🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Elizabeth K. Lee

University of Minnesota, Duluth

ORCID: 0000-0001-7533-7853

Also affiliated with Dana-Farber Cancer Institute

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

1.9DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more